Beyond The Printed Page

  1. A Behind The Scenes Look Into Enanta’s CEO, Jay Luly 2/22/2021

    From Big Pharma, to small biotech, to a VC, and then back to small biotech, Jay Luly, Ph.D., CEO of Enanta Pharmaceuticals, has seen his fair share of change in this ever-changing industry. 

  2. We Need To Expand How We Value Companies 1/25/2021

    During an interview for an upcoming feature in Life Science Leader, Sanjeev Redkar, Ph.D., cofounder and president of Apollomics (a biopharmaceutical company discovering and developing oncology treatments), discussed the topic of an exit strategy.

  3. Have You Heard Of The Chinese Biopharmaceutical Association (CBA)? 1/19/2021

    While working at his first job at Human Genome Sciences in 1995, Guo-Liang Yu, Ph.D., decided to create The Chinese Biopharmaceutical Association (CBA), one of the largest Chinese American professional associations in the U.S.

  4. What 4 Biopharma CFOs Think About The Future Of Remote Work 1/11/2021

    While we touch on remote work in Life Science Leader’s annual outlook issue, the responses in this article from four biopharmaceutical CFOs to questions on the subject shed additional light on the challenge that lies ahead for employers.

  5. Where Does Biopharma’s Future Reside Beyond Boston And San Francisco? 1/4/2021

    Two metropolitan areas tend to dominate the discussion when it comes to key biopharmaceutical industry hubs within the United States — Boston and San Francisco. And while these two cities have certainly earned their biopharma bragging rights over the years, one has to wonder how long that will continue. Afterall, just a few years ago biopharmaceutical executives noted it becoming increasingly difficult to attract top talent, as candidates cited “too crowded,” “too expensive,” and a host of other reasons behind their unwillingness to move to places like Boston and San Francisco. But does location (for many roles) even still apply?

  6. Why Treat The Eye Through The Nose? 12/23/2020

    Jeffrey Nau, Ph.D., president and CEO of Oyster Point Pharma and subject of upcoming feature in Life Science Leader, explains the scientific rationale behind treating dry eye disease (DED) using nasal spray as a method of delivery. 

  7. A Behind The Scenes Peek Into Oyster Point Pharma’s CEO, Jeffrey Nau 12/21/2020

    Jeffrey Nau, Ph.D., president and CEO of Oyster Point Pharma and subject of an upcoming feature in Life Science Leader, shares some of the more personal experiences encountered during life’s journey to the c-suite. 

  8. 4 Biopharma Finance Execs Tackle Tough R&D Topics 12/21/2020

    In this special addition to our outlook issue, these finance experts discuss COVID’s effects on the industry and what needs to be done to encourage the allocation of resources to develop and commercialize drugs for common chronic diseases for the future.

  9. 7 Biopharma CEOs On Who And What To Pay Attention To In 2021 And Beyond 12/17/2020

    For this Beyond The Printed Page installment, six biopharmaceutical company CEOs give their perspectives on companies, people, trends, and technologies they are paying attention to for 2021 and beyond.

  10. 6 CEOs Weigh In On The Supply Chain, Nationalism, And The Reshoring Of Biopharma Manufacturing 12/14/2020

    Most of us knew that a significant amount of biopharma manufacturing had been offshored to places like China and India. However, most of us (despite Louis Garguilo having written about this as a problem rising on the horizon for years), never thought a supposed trade ally would ever actually use this as a point of leverage to try to get its way.